• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Notes

No. Proposition For Against Abstain
1

Election of Class I Director for a three-year term expiring at the 2029 annual meeting of shareholders: Robert Hershberg, PhD, MD

2

Election of Class I Director for a three-year term expiring at the 2029 annual meeting of shareholders: Katey Owen, PhD

3

To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.

4

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.